Preclinical disposition and pharmacokinetics of volitinib, a novel selective cMet inhibitor.

被引：7
|
作者：
Gu, Yi [1 ]
Sai, Yang [1 ]
Wang, Jian [1 ]
Xia, Sumei [1 ]
Wang, Guanglin [1 ]
Zhao, Yuansheng [1 ]
Zhang, Li [1 ]
Yang, Wenqing [1 ]
Dai, Guangxiu [1 ]
Zhang, Weihan [1 ]
Gong, Qisun [1 ]
Tian, Zhenping [1 ]
Su, Weiguo [1 ]
机构：
[1] Hutchison MediPharma Ltd, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-3371
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3371
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor
    Gu, Yi
    Sai, Yang
    Wang, Jian
    Yu, Meijing
    Wang, Guanglin
    Zhang, Li
    Ren, Hongcan
    Fan, Shiming
    Ren, Yongxin
    Qing, Weiguo
    Su, Weiguo
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 136
  • [2] Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics
    Yi Gu
    Jian Wang
    Ke Li
    Li Zhang
    Hongcan Ren
    Lixia Guo
    Yang Sai
    Weihan Zhang
    Weiguo Su
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 95 - 115
  • [3] Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics
    Gu, Yi
    Wang, Jian
    Li, Ke
    Zhang, Li
    Ren, Hongcan
    Guo, Lixia
    Sai, Yang
    Zhang, Weihan
    Su, Weiguo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 95 - 115
  • [4] Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor.
    Yamakawa, Hiroko
    Mizutani, Akio
    Arikawa, Yasuyoshi
    Ebara, Shunsuke
    Satoh, Yoshihiko
    Morishita, Daisuke
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor.
    Brandhuber, Barbara
    Ku, Karin
    Lallena, Maria J.
    Baquero, Carmen
    Choy, Regina
    Ebata, Kevin
    Lin, Sophie Shu
    Jiang, Lihua
    Liu, Yanxin
    Chen, Xiangling
    Lou, Liguang
    CANCER RESEARCH, 2021, 81 (13)
  • [6] Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor.
    He, Kan
    He, Bing
    Grace, James E.
    Xin, Baomin
    Zhang, Donglu
    Pinto, Donald J.
    Luettgen, Joseph M.
    Knabb, Robert M.
    Lam, Patrick Y. S.
    Wexler, Ruth R.
    Humphreys, William G.
    Shyu, Wen-Chyi
    Grossman, Scott J.
    BLOOD, 2006, 108 (11) : 273A - 273A
  • [7] Phase I studies of a selective cMet inhibitor AZD6094 (HMPL504/volitinib) in patients with advanced solid tumors
    Hua, Ye
    Shen, Lin
    Gan, Hui
    Lickliter, Jason
    Millward, Michael
    Xu, Jianming
    Wang, Jian
    Sai, Yang
    Su, Weiguo
    Frigault, Melanie M.
    Qi, Chuan
    CANCER RESEARCH, 2015, 75
  • [8] Nonclinical in vitro ADME, disposition, and pharmacokinetic assessment of ARQ 092, a selective AKT inhibitor.
    Volak, Laurie P.
    Bresciano, Karen R.
    Hall, Terence
    Vensel, David
    Lapierre, Jean-Marc
    Smukste, Inese
    McKearn, David K.
    Savage, Ronald E.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [9] Preclinical Pharmacokinetics and in vitro Metabolism of FHND5071, a Novel Selective RET Kinase Inhibitor
    Han, Yiran
    Wen, Tiantian
    Wang, Jia
    Shi, Jinmiao
    Zhu, Yongqiang
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2023, 48 (05) : 595 - 614
  • [10] Preclinical Pharmacokinetics and in vitro Metabolism of FHND5071, a Novel Selective RET Kinase Inhibitor
    Yiran Han
    Tiantian Wen
    Jia Wang
    Jinmiao Shi
    Yongqiang Zhu
    European Journal of Drug Metabolism and Pharmacokinetics, 2023, 48 : 595 - 614
12345